<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05610878</url>
  </required_header>
  <id_info>
    <org_study_id>CEMB-SC01</org_study_id>
    <nct_id>NCT05610878</nct_id>
  </id_info>
  <brief_title>Efficacy of Preconditioned Adipose-Derived Stem Cells in Fat Grafting</brief_title>
  <official_title>Supplementation of Autologous Fat Grafts With Curcumin Preconditioned Adipose-Derived Stem Cells in the Treatment of Facial Contour Deformities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of the Punjab</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre of Excellence in Molecular Biology, University of the Punjab, Lahore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Higher Education Commission (Pakistan)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jinnah Burn and Reconstructive Surgery Centre, Lahore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of the Punjab</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the comparison of therapeutic potential of curcumin&#xD;
      preconditioned adipose derived stem cells (ASCs) enrichment fat grafting, naïve ASCs&#xD;
      enrichment fat grafting and conventional fat grafting to correct facial contour deformities&#xD;
      that cause aesthetic complications in patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Human subcutaneous adipose tissue along informed consents will be collected in a lipoaspirate&#xD;
      container or 20 cc B.D syringes under the sterilized conditions during the surgery. Fat&#xD;
      aspirate collection will be based on certain selection criteria including pre-requisitioning&#xD;
      non-diabetic, negative viral status patients. Adipose derived stem cells (ASCs) will be&#xD;
      isolated from adipose tissue under sterile aseptic conditions. Firstly, the lipoaspirate&#xD;
      container will be opened in the biosafety cabinet and drain off the blood carefully with the&#xD;
      help of serological pipette. Then, fat will be washed thrice with 1X phosphate buffer saline&#xD;
      (PBS) containing antibiotic and anti-mycotic solution, in order to get rid of blood vessels,&#xD;
      hair and other type of connective tissue. After that, the tissue will be enzymatically&#xD;
      digested with collagenase type I solution (1mg/ml prepared in Low Glucose Dulbecco's Modified&#xD;
      Eagle Medium (LG-DMEM) and incubate for 45 minutes at 37°C on a shaker. After digestion, the&#xD;
      enzyme will be inactivated by LG-DMEM augmented with 5% freshly isolated human serum and spin&#xD;
      at 1200 rpm for 10 minutes. After centrifugation, fat will be discarded and the infranatant&#xD;
      will be passed through 100 µm cell strainers to remove the debris. The filtrate will be&#xD;
      centrifuged again for 1200rpm for 8 minutes. Pellet will be resuspended and plated in a&#xD;
      sterile T-75 cm2 flask containing 10 ml LG-DMEM supplemented with 5% human serum. The flask&#xD;
      will be placed in a humidified incubator at 37°C, 5% carbon dioxide (CO2). The media will be&#xD;
      replenished after every third day until the cells got 80-90 % confluency. Cells of P2-P3&#xD;
      stage will be used in this study for immunocytochemistry, and intervention as well. For&#xD;
      preconditioning, ASCs will be incubated with curcumin preconditioned medium for 24 h. Cell&#xD;
      sterility and viability will be assessed prior to transplantation. For transplantation,&#xD;
      1,00,000 cells per ml of fat will be mixed, transferred to 10 cc syringes and injected at&#xD;
      deformity site. Amount of fat will be predetermined by the clinician on the basis of facial&#xD;
      asymmetry.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volumetric change in facial tissue by ultrasonography</measure>
    <time_frame>9 months</time_frame>
    <description>Volumetric evaluation of treated area will be done by measuring the thickness of subcutaneous tissue (in millimeters) by using baseline B mode ultrasound device. Volumetric evaluation of treated area will be done by measuring the thickness of subcutaneous tissue (in millimeters) before transplantation, 1 week after transplantation then after 3, 6 and 9 months by using baseline B mode ultrasound device.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Assessment</measure>
    <time_frame>9 months</time_frame>
    <description>Patients will be interviewed and pre-and post-operatively and digital images will be taken until 9 months of follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgeon Assessment</measure>
    <time_frame>9 months</time_frame>
    <description>Patients will be visually inspected for facial volume by two qualified plastic surgeons unaware of treatment after grafting to check whether curcumin pretreatment have effect on MSCs origin of ASCs.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Romberg Disease</condition>
  <condition>Craniofacial Microsomia</condition>
  <condition>Burn Scar</condition>
  <condition>Post-Traumatic Scar (Disorder)</condition>
  <arm_group>
    <arm_group_label>Cultured ASCs enrichment fat grafting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fat graft will be supplemented with naïve ASCs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Curcumin-preconditioned ASCs enrichment fat grafting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fat graft will be augmented with curcumin preconditioned ASCs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional fat grafting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fat graft will not be supplemented with ex-vivo expanded ASCs</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cultured ASCs enrichment fat grafting</intervention_name>
    <description>Patients will undergo conventional fat harvesting. Harvested fat will be mixed with cultured ASCs and grafted into recipient site with 1,00,000 cells/ml injected fat</description>
    <arm_group_label>Cultured ASCs enrichment fat grafting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Curcumin-preconditioned ASCs enrichment fat grafting</intervention_name>
    <description>Patients will undergo conventional fat harvesting. Harvested fat will be mixed with cultured ASCs preconditioned with curcumin and grafted into recipient site with 1,00,000 cells/ml injected fat</description>
    <arm_group_label>Curcumin-preconditioned ASCs enrichment fat grafting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional fat grafting</intervention_name>
    <description>Patients will undergo conventional fat harvesting and grafting of fat into recipient site</description>
    <arm_group_label>conventional fat grafting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Age 18-50 years (male or female)&#xD;
&#xD;
          -  Body-mass index 20-30 kg/m²&#xD;
&#xD;
          -  Suitable for liposuction as assessed by the expected cosmetic results&#xD;
&#xD;
          -  Provided signed informed consent&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Systemic disorders include autoimmune diseases, hemorrhagic diseases, bone marrow&#xD;
             aplasia, sepsis, cancer, and others&#xD;
&#xD;
          -  Local disorders include acne, infections and others&#xD;
&#xD;
          -  Risk factors include smoking, uncompensated diabetes, hypertension, and allergy to the&#xD;
             drugs used for general anesthesia&#xD;
&#xD;
          -  Microbiological contamination of either the cell culture or the transplanted tissue&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Azra Mehmood, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center of Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sheikh Riazuddin, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Jinnah Burn and Reconstructive Surgery Center (JB&amp;RSC), Lahore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Azra Mehmood, PhD</last_name>
    <phone>+92-333-4107008</phone>
    <email>azra_mehmood@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amna Arif, M.Phil.</last_name>
    <phone>+92-333-4161068</phone>
    <email>amnaarif.qureshi@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stem Cell Laboratory, Jinnah Burn and Reconstructive Surgery Center (JB&amp;RSC)</name>
      <address>
        <city>Lahore</city>
        <state>Punjab</state>
        <zip>54550</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Moazzam Nazeer Tarar, Plastic Surgeon MBBS/ FRCS</last_name>
      <phone>+92-300-8423139</phone>
      <email>mntarar@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <reference>
    <citation>Matsumoto D, Sato K, Gonda K, Takaki Y, Shigeura T, Sato T, Aiba-Kojima E, Iizuka F, Inoue K, Suga H, Yoshimura K. Cell-assisted lipotransfer: supportive use of human adipose-derived cells for soft tissue augmentation with lipoinjection. Tissue Eng. 2006 Dec;12(12):3375-82. doi: 10.1089/ten.2006.12.3375.</citation>
    <PMID>17518674</PMID>
  </reference>
  <reference>
    <citation>Bashir MM, Sohail M, Ahmad FJ, Choudhery MS. Preenrichment with Adipose Tissue-Derived Stem Cells Improves Fat Graft Retention in Patients with Contour Deformities of the Face. Stem Cells Int. 2019 Nov 20;2019:5146594. doi: 10.1155/2019/5146594. eCollection 2019.</citation>
    <PMID>31827528</PMID>
  </reference>
  <reference>
    <citation>Ghufran H, Mehmood A, Azam M, Butt H, Ramzan A, Yousaf MA, Ejaz A, Tarar MN, Riazuddin S. Curcumin preconditioned human adipose derived stem cells co-transplanted with platelet rich plasma improve wound healing in diabetic rats. Life Sci. 2020 Sep 15;257:118091. doi: 10.1016/j.lfs.2020.118091. Epub 2020 Jul 12.</citation>
    <PMID>32668325</PMID>
  </reference>
  <reference>
    <citation>D.A. Bourne, F.M. Egro, J. Bliley, I. James, G.L. Haas, E.M. Meyer, V. Donnenberg, A. Donnenberg, B. Branstetter, K. Marra, Abstract QS11: stem cell therapy enriched fat graft reconstruction of craniofacial deficits, Plastic and Reconstructive Surgery Global Open 6(4 Suppl) (2018).</citation>
  </reference>
  <reference>
    <citation>Cao Z, Li H, Wang ZH, Liang XQ. High-Density Fat Grafting Assisted Stromal Vascular Fraction Gel in Facial Deformities. J Craniofac Surg. 2022 Jan-Feb 01;33(1):108-111. doi: 10.1097/SCS.0000000000008038.</citation>
    <PMID>34519702</PMID>
  </reference>
  <reference>
    <citation>Wang C, Long X, Si L, Chen B, Zhang Y, Sun T, Zhang X, Zhao RC, Wang X. A pilot study on ex vivo expanded autologous adipose-derived stem cells of improving fat retention in localized scleroderma patients. Stem Cells Transl Med. 2021 Aug;10(8):1148-1156. doi: 10.1002/sctm.20-0419. Epub 2021 Apr 19.</citation>
    <PMID>33871949</PMID>
  </reference>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>October 26, 2022</study_first_submitted>
  <study_first_submitted_qc>November 3, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2022</study_first_posted>
  <last_update_submitted>November 3, 2022</last_update_submitted>
  <last_update_submitted_qc>November 3, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of the Punjab</investigator_affiliation>
    <investigator_full_name>Azra Mehmood</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Facial deformities</keyword>
  <keyword>Fat grafting</keyword>
  <keyword>Adipose derived stem cells</keyword>
  <keyword>Preconditioning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Goldenhar Syndrome</mesh_term>
    <mesh_term>Facial Hemiatrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

